Axitinib in advanced renal-cell carcinoma
- PMID: 24206641
- DOI: 10.1016/S1470-2045(13)70499-6
Axitinib in advanced renal-cell carcinoma
Erratum in
- Lancet Oncol. 2014 Mar;15(3):e106
Comment on
-
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25. Lancet Oncol. 2013. PMID: 24206640 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
